SCHEMBL1880326

SCHEMBL1880326

Cc1cc(-c2sc(NC(=O)NCC(=O)N(C)C)nc2C)nc(N(C)CCN(C)C)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 3/20 0.42
PRMT3 O60678 1/20 0.35
PI4KB Q9UBF8 6/20 0.35
PIK3CG P48736 5/20 0.35
PIK3CD O00329 3/20 0.35
PIK3CB P42338 2/20 0.35
DYRK3 O43781 1/20 0.35
MAP4K4 O95819 1/20 0.35
CLK2 P49760 1/20 0.35
DYRK1A Q13627 1/20 0.35
MINK1 Q8N4C8 1/20 0.35
CLK4 Q9HAZ1 1/20 0.35
ALDH1A1 P00352 3/20 0.34
MAPT P10636 2/20 0.34
HTT P42858 2/20 0.34
HSD17B10 Q99714 2/20 0.34
KDM4E B2RXH2 1/20 0.34
HPGD P15428 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HCRTR1 O43613 4/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1888434 0.85 PIK3CG (0.48) PIK3CAPI4KBPIK3CGPIK3CDPIK3CB
SCHEMBL1884085 0.81 GAA (0.38) PIK3CAPRMT3PI4KBPIK3CGPIK3CD
SCHEMBL16762562 0.80 PIK3CA (0.40) PIK3CAPRMT3PI4KBPIK3CGPIK3CD
SCHEMBL1881199 0.80 PRMT3 (0.36) PIK3CAPRMT3PI4KBPIK3CGPIK3CD
SCHEMBL1883147 0.79 PIK3CD (0.43) PIK3CAPRMT3PI4KBPIK3CGPIK3CD
SCHEMBL1883557 0.78 PIK3CG (0.44) PIK3CAPI4KBPIK3CGPIK3CDPIK3CB
SCHEMBL1884087 0.78 PIK3CA (0.39) PIK3CAPI4KBPIK3CGPIK3CDPIK3CB
SCHEMBL1889113 0.78 PIK3CA (0.56) PIK3CAPI4KBPIK3CGPIK3CDPIK3CB
SCHEMBL1881946 0.77 PIK3CG (0.44) PIK3CAPI4KBPIK3CGPIK3CDPIK3CB
SCHEMBL1885504 0.77 PIK3CG (0.45) PIK3CAPI4KBPIK3CGPIK3CDPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130172349-A1 INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE NOVARTIS AG (CH) 2013-07-04 US disclosed
US-8404684-B2 Inhibitors of phosphatidylinositol 3-kinase NOVARTIS AG (CH) 2013-03-26 US disclosed
US-20110105535-A1 INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE NOVARTIS AG 2011-05-05 US disclosed
EP-2157091-A1 Inhibitors of phosphatidylinositol 3-kinase Novartis AG (CH) 2010-02-24 EP disclosed
EP-1622897-B1 INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE NOVARTIS AG (CH) 2009-10-14 EP disclosed
US-20070032487-A1 Inhibitors of phosphatidylinositol 3-kinase NOVARTIS AG (CH) 2007-02-08 US disclosed
EP-1622897-A1 INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE Novartis AG (CH) 2006-02-08 EP disclosed
WO-2004096797-A1 INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE NOVARTIS AG (CH) 2004-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032487-A1 Inhibitors of phosphatidylinositol 3-kinase PIK3CA, PIP4K2C, PIP4K2B PIK3CA 1/4885PRMT3 758/4885PI4KB 17/4885
US-20110105535-A1 INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE PIK3CA, PIK3CD, PIP4K2C PIK3CA 1/4885PRMT3 746/4885PI4KB 20/4885
US-20130172349-A1 INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE PIK3CA, PIK3CD, PIP4K2C PIK3CA 1/4885PRMT3 746/4885PI4KB 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.